Kenneth J. Nussbacher
Profile
Kenneth J.
Nussbacher formerly worked at Symyx Technologies, Inc., as Director from 1995 to 2008, Standard BioTools, Inc., as Director from 2003 to 2012, Achaogen, Inc., as Director, Allopartis Biotechnologies, Inc., as Director, Presage Biosciences, Inc., as Director, XenoPort, Inc., as Independent Director from 2000 to 2010, Predicant Biosciences, Inc., as Director from 2002 to 2006, Pathwork Diagnostics, Inc., as Director, Affymetrix, Inc., as Executive Vice President from 1995 to 2000, Affymax Research Institute, as Executive Vice President-Business & Legal Affairs, and Affymax NV, as Executive Vice President-Business & Legal Affairs.
Mr. Nussbacher received his graduate degree from Duke University and undergraduate degree from The Cooper Union for the Advancement of Science & Art.
Former positions of Kenneth J. Nussbacher
Companies | Position | End |
---|---|---|
XENOPORT, INC. | Director/Board Member | - |
Affymax NV | General Counsel | 2008-07-16 |
Symyx Technologies, Inc.
Symyx Technologies, Inc. Packaged SoftwareTechnology Services Symyx Technologies, Inc. develops and applies high-throughput experimentation to the discovery of materials for chemical and petrochemical, pharmaceutical development, electronics, consumer goods and automotive customers. The company works together with companies seeking to transform their search for better products and processes through research collaborations and Discovery Tools sales and the license of materials, intellectual property and software. The company was incorporated in February 1999 and is headquartered in Sunnyvale, CA. | Director/Board Member | 2008-06-15 |
Predicant Biosciences, Inc.
Predicant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Predicant Biosciences, Inc. is a life sciences company, which used to develop minimally invasive technology for identifying and assaying protein biomarker patterns that reflect and differentiate biological states. It was founded in 2002 and was located in San Francisco, CA | Director/Board Member | 2006-07-05 |
AFFYMETRIX, INC. | Corporate Officer/Principal | 1999-12-31 |
Training of Kenneth J. Nussbacher
Duke University | Graduate Degree |
The Cooper Union for the Advancement of Science & Art | Undergraduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
STANDARD BIOTOOLS INC. | Health Technology |
Private companies | 10 |
---|---|
Symyx Technologies, Inc.
Symyx Technologies, Inc. Packaged SoftwareTechnology Services Symyx Technologies, Inc. develops and applies high-throughput experimentation to the discovery of materials for chemical and petrochemical, pharmaceutical development, electronics, consumer goods and automotive customers. The company works together with companies seeking to transform their search for better products and processes through research collaborations and Discovery Tools sales and the license of materials, intellectual property and software. The company was incorporated in February 1999 and is headquartered in Sunnyvale, CA. | Technology Services |
Pathwork Diagnostics, Inc.
Pathwork Diagnostics, Inc. Medical SpecialtiesHealth Technology Pathwork Diagnostics Inc. develops and delivers molecular diagnostics for oncology. The company was founded by Glenda Anderson, Richard Zare, and George M. Whitesides in 2003 and is headquartered in Redwood City, CA. | Health Technology |
XenoPort, Inc.
XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |
Predicant Biosciences, Inc.
Predicant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Predicant Biosciences, Inc. is a life sciences company, which used to develop minimally invasive technology for identifying and assaying protein biomarker patterns that reflect and differentiate biological states. It was founded in 2002 and was located in San Francisco, CA | Health Technology |
Achaogen, Inc.
Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Affymetrix, Inc.
Affymetrix, Inc. Medical SpecialtiesHealth Technology Affymetrix, Inc. develops, manufactures and sells products and services for genetic analysis. The company was founded by Stephen P. A. Fodor in 1992 and is headquartered in Santa Clara, CA. | Health Technology |
Allopartis Biotechnologies, Inc.
Allopartis Biotechnologies, Inc. BiotechnologyHealth Technology Allopartis Technologies Inc. develops industrial and therapeutic proteins. The company was founded by Robert Blazej, Charles Emrich and Nicholas Toriello in 2008 and is headquartered in San Francisco, CA. | Health Technology |
Affymax NV | Health Technology |
Affymax Research Institute
Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Commercial Services |
Presage Biosciences, Inc.
Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Kenneth J. Nussbacher